Search

Introduction. Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), constitute a group of chronic inflammatory conditions affecting the digestive system. The etiology of these conditions is complex, resulting from the interaction of genetic factors with environmental factors, lifestyle, and intestinal dysbiosis. The diagnosis is established based on clinical examination and general and specific paraclinical examinations (fecal calprotectin, digestive endoscopy). The most frequent intestinal complications are strictures for both IBDs, and in CD, fistulas and abscesses, especially perianal ones, may occur. There is no curative treatment for IBD; pharmacological therapy includes immunomodulatory drugs and monoclonal antibodies. Quality of life. To quantify patients’ quality of life more objectively, various questionnaires have been developed and implemented. Patients with IBD have significantly lower quality of life than healthy individuals. Multidisciplinary team. As IBD are chronic pathologies with a long and unpredictable course, they require high-quality management as early as possible from the time of diagnosis. The key to achieving the best outcomes is the multidisciplinary patient-oriented care. Conclusions. Evaluating the quality of life of patients with IBD is essential for several reasons. A multidisciplinary team, involving the family physician, gastroenterologist, psychologist, or other specialists, is essential for providing quality care to these patients. [ABSTRACT FROM AUTHOR]

Inflammatory bowel diseases (IBD) are a group of conditions characterized by chronic inflammation of the digestive tract segments. These diseases are multifactorial conditions with an increased prevalence in modern society, a consequence of genetic and environmental factors. The main IBD are ulcerative colitis and Crohn's disease, which have many similarities but differ by localization in the digestive tract and by the degree of histopathological damage. The groups of drugs used in the treatment of IBD are: aminosalicylates, corticosteroids, antibiotics, immunomodulators and biological agents. Although there has been a lot of progress in the treatment of these diseases, currently there is no curative treatment. [ABSTRACT FROM AUTHOR]

Inflamatory bowel diseases are chronic and disabling for patients with many complications and so they need special attention in diagnosis, treatment and monitoring. There is scientific proof that treating patients in dedicated centers, by inflammatory bowel disease experts, is more successfull than treating them in a regular one by community gastroenterologists. Furthermore, there is also a great difference between some of these centers regarding the treatment and the screening of dysplasia and colorectal cancer, as the example of Brigham and Women’s Hospital in Boston stands. In these last years, the most important gastroenterology associations have released a bunch of guides that stand for the same quality measures such as recommending steroid-sparing therapy after 60 days, influenza and penumococcal vaccine, assesing for HBV and TB, before anti-TNF treatment and also dysplasia surveillance. [ABSTRACT FROM AUTHOR]